IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Average Recommendation of "Moderate Buy" by Brokerages

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $533.75.

IDXX has been the topic of several research analyst reports. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday. Barclays lifted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Finally, Leerink Partners began coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock.

Remove Ads

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded up $1.09 during midday trading on Friday, hitting $430.12. The company had a trading volume of 654,250 shares, compared to its average volume of 542,991. The business's 50 day simple moving average is $437.37 and its two-hundred day simple moving average is $449.41. The stock has a market cap of $34.98 billion, a PE ratio of 40.31, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories has a 1-year low of $398.50 and a 1-year high of $562.25.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its holdings in IDEXX Laboratories by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock worth $948,279,000 after purchasing an additional 37,734 shares during the last quarter. Bamco Inc. NY raised its holdings in IDEXX Laboratories by 4.3% during the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock worth $829,163,000 after purchasing an additional 82,264 shares during the last quarter. Franklin Resources Inc. raised its holdings in IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock worth $675,259,000 after purchasing an additional 34,305 shares during the last quarter. Invesco Ltd. raised its holdings in IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after purchasing an additional 74,324 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $412,258,000. 87.84% of the stock is owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.